- Details
- Description
About Anamorelin
Anamorelin (developmental code names ONO-7643, RC-1291, ST-1291), also known as anamorelin hydrochloride (USAN, JAN), is a non-peptide, orally-active, centrally-penetrant, selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR) with appetite-enhancing and anabolic effects which is development for the treatment of cancer cachexia and anorexia.
Anamorelin significantly increases plasma levels of growth hormone (GH), insulin-like growth factor 1 (IGF-1), and insulin-like growth factor-binding protein 3 (IGFBP-3) in humans, without affecting plasma levels of prolactin, cortisol, insulin, glucose, adrenocorticotropic hormone (ACTH), luteinizing hormone (LH), follicle-stimulating hormone (FSH), or thyroid-stimulating hormone (TSH). In addition, anamorelin significantly increases appetite, overall body weight, lean body mass, and muscle strength,with increases in body weight correlating directly with increases in plasma IGF-1 levels.
Indication
Cancer cachexia in the following malignant tumors:
Non-small cell lung cancer, gastric cancer, pancreatic cancer and colorectal cancer
Dosage and administration
Usually, for adults, administer 100 mg of anamorelin hydrochloride at fasting state orally once a day.
Do not eat within 1 hour after taking this medicine. If you do not notice weight gain or improvement in appetite, in principle, you should stop taking it 3 weeks after starting.
